Avanafil

Avanafil
	Avanafil is a PDE5 inhibitor
Clinical data
Trade names	Stendra
AHFS/Drugs.com	Monograph
MedlinePlus	a614010
License data	EU EMA: by INN; US DailyMed: Avanafil; US FDA: Avanafil;
Routes of; administration	By mouth
ATC code	G04BE10 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (S)-4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide;
CAS Number	330784-47-9 ;
PubChem CID	9869929;
IUPHAR/BPS	7448;
DrugBank	DB06237 ;
ChemSpider	8045620 ;
UNII	DR5S136IVO;
KEGG	D03217 ;
ChEBI	CHEBI:66876;
ChEMBL	ChEMBL1963681 ;
PDB ligand	E6L (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID50186727 ;
Chemical and physical data
Formula	C23H26ClN7O3
Molar mass	483.96 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1c(OC)ccc(c1)CNc3nc(ncc3C(=O)NCc2ncccn2)N4[C@@H](CCC4)CO;
	InChI InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1 ; Key:WEAJZXNPAWBCOA-INIZCTEOSA-N ;
	(what is this?) (verify)

Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is sold under the brand names Stendra and Spedra. It was invented at Mitsubishi Tanabe Pharma, formerly known as Tanabe Seiyaku Co., and licensed to Vivus Inc., which partnered with Menarini Group to commercialise Spedra in over forty European countries, Australia, and New Zealand. Metuchen Pharmaceuticals obtained exclusive rights within the United States.

Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme found in various body tissues, primarily in the corpus cavernosum penis. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum serum concentration in about thirty to forty-five minutes. About two-thirds of the participants were able to engage in sexual activity within fifteen minutes.